5-Star Stocks Poised to Pop: ChemoCentryx

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company ChemoCentryx (Nasdaq: CCXI  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at ChemoCentryx's business and see what CAPS investors are saying about the stock right now.

ChemoCentryx facts

Headquarters (Founded) Mountain View, Calif. (1997)
Market Cap $425.4 million
Industry Biotechnology
Trailing-12-Month Revenue $29.6 million
Management Founder/Chairman/CEO Dr. Thomas Schall
CFO Susan Kanaya
Trailing-12-Month Return on Equity (10.9%)
Cash/Debt $131.6 million / $1.2 million
Competitors Abbott Labs
Amgen
AstraZeneca

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, all 18 members who have rated ChemoCentryx believe the stock will outperform the S&P 500 going forward.   

Earlier this week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bull case for our community:

I see ChemoCentryx as undervalued at this level given their multiple compounds in advanced clinical trials for various indications and a strong partnership with [GlaxoSmithKline].

Having IPO'd just a few months ago, ChemoCentryx is weakly followed and lacks objective vetting. However, their chemokine receptor focus has been extensively validated by academic research and has been addressed by other biopharmas. ...

The company is somewhat reticent when it comes to updating the progress of ongoing studies, but I believe once the street becomes more aware of the four ongoing SHIELD phase III trials being run by Glaxo for moderate-to-severe Crohn's the [market cap] will break 600M. Meanwhile the company is well-capitalized with a strong balance sheet.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, ChemoCentryx may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2014873, ~/Articles/ArticleHandler.aspx, 9/21/2014 12:09:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement